Thomas Kleen

Thomas Kleen

Company: Immodulon Therapeutics

Job title: Chief Scientific Officer

Bio:

Dr. Kleen is Chief Scientific Officer and part of the senior management team of Immdulon contributing his significant knowledge and strategic expertise in the development of cancer immunotherapies to Immodulon’s pipeline. He is responsible to further advance Immodulon’s lead candidate, IMM-101 and the company’s pre-clinical and clinical research and development, as well strategic industry and academic collaborations and Immodulon’s biomarker strategy. .  Prior he was Executive VP Immune Monitoring at Epiontis/Precison for Medicine. He received his PhD in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany.  During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections.  He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematological disorders and malignancies after treatment with full myelo-ablative regimens. Since 2009 Dr. Kleen is member of the SITC-FDA Task Force on Immunotherapy Biomarkers, which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.

Seminars:

Clinical Biomarker Strategy With a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget 8:30 am

Identification and validation of circulatory immunological biomarkers in cancer patients remains a major challenge during clinical trials and assessment of therapeutic responses Novel technologies and classic immunological biomarkers each offer benefits and challenges that should be evaluated before their use  A sample clinical biomarker strategy for IMM-101 a multitargeted immunomodulator of the innate and adaptive…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.